NYSE · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Glass House Brands Inc. GLAS
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$182.0M
▼ 9.4% vs FY2024
EPS · FY25
$-0.55
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-31.2%
Net margin · FY25
-16.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 182.0M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 16 cents on every revenue dollar this year.
Per share
USD -0.55
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-31.2%
Return on equity, FY2025
ROE
Operating margin-9.1%
Net margin-16.3%
Return on assets-9.4%
Each USD of equity lost 31 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+30.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+28.9%
+30.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 318.6M
total assets, end of FY2025
Total assetsUSD 318.6M
EquityUSD 73.9M
CashUSD 23.4M
Gross debtUSD 68.7M
Net debtUSD 45.3M
Current ratio1.78×
Net debt stands at 61% of equity.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.2
0.2
0.2
0.1
0.1
0.0
Operating income $B
−0.0
0.0
−0.0
−0.1
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
−0.0
0.0
0.0
Net income $B
−0.0
0.0
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−0.55
−0.21
−1.62
−0.83
−1.11
−0.78
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−31.2
0.5
−76.0
−18.7
−41.4
−63.4
Shares out B
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed